Recent advancements in interventional cardiology focus on identifying and treating coronary lesions prone to future cardiovascular events. The bioresorbable magnesium scaffold (DREAMS 3G) represents a significant leap in this field. While clinicians often debate the invasive treatment of high-risk plaques, newer scaffold technologies offer a temporary structural solution. The BIOMAG-I study provides critical evidence regarding the vascular response of these specific plaques to the DREAMS 3G system.

Clinical Performance of the Bioresorbable Magnesium Scaffold

Researchers conducted a post-hoc analysis of the BIOMAG-I study to evaluate how high-risk plaque morphology affects late lumen loss (LLL). They defined high-risk plaques using advanced imaging metrics, specifically a micro-vessel density (μFR) of ≤0.80 and a plaque burden (PB) of ≥70%. Surprisingly, the results indicated that patients with high-risk plaques achieved similar LLL outcomes at follow-up compared to those with lower-risk lesions. This suggests that the scaffold provides consistent luminal support regardless of the underlying plaque vulnerability.

Furthermore, the study stratified subgroups based on the presence of a minimum lumen area (MLA) <3.5 mm². Even in these more constricted vessels, the scaffold demonstrated robust performance. Magnesium alloys disappear after the initial healing phase, which prevents long-term foreign body reactions. Consequently, this technology might resolve the historical concerns associated with permanent metallic drug-eluting stents. Therefore, physicians can consider this as a viable alternative for complex lesion management.

Additionally, the use of intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in BIOMAG-I allowed for precise tracking of vascular remodeling. The bioresorbable magnesium scaffold maintained its radial strength during the critical first few months. Subsequently, it resorbed almost completely by 12 months. This timeline matches the vessel's natural healing process, thereby reducing the risk of late stent thrombosis and allowing for the restoration of natural vasomotion.

Frequently Asked Questions

What is a high-risk coronary plaque?

A high-risk plaque is a coronary lesion that is more likely to rupture and cause a heart attack. In the BIOMAG-I study, these were identified by high plaque burden and low fractional flow reserve (via imaging).

How does the DREAMS 3G scaffold differ from traditional stents?

Unlike traditional drug-eluting stents that remain in the artery forever, the DREAMS 3G magnesium scaffold provides temporary support and then fully resorbs into the body within approximately 12 months.

Why is late lumen loss (LLL) significant?

Late lumen loss measures the reduction in the size of the artery opening after a procedure. Low LLL indicates that the vessel has remained open and successfully resisted restenosis (re-narrowing).

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Rubio PM et al. Outcomes of Patients With High-Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG-I Study. Catheter Cardiovasc Interv. 2026 Jun 07. doi: 10.1002/ccd.70655. PMID: 42252499.

Haude M et al. Clinical outcomes of the third-generation resorbable magnesium scaffold for coronary artery lesions: three-year results of the BIOMAG-I study. EuroIntervention. 2025 Apr 14;21:971-973. doi: 10.4244/EIJ-D-25-00396.

Seguchi M et al. Preclinical evaluation of the degradation kinetics of third generation resorbable magnesium scaffolds. EuroIntervention. 2023;18:10.4244/EIJ-D-22-00718.